Focused On-demand Library for ETS domain-containing transcription factor ERF

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P50548

UPID:

ERF_HUMAN

Alternative names:

Ets2 repressor factor; PE-2

Alternative UPACC:

P50548; B2RAP1; B7Z4R0; Q59G38; Q9UPI7

Background:

ETS domain-containing transcription factor ERF, also known as Ets2 repressor factor or PE-2, plays a crucial role in cellular processes. It acts as a potent transcriptional repressor, binding to the H1 element of the Ets2 promoter, and is pivotal in regulating genes involved in cellular proliferation. ERF is essential for various developmental processes, including extraembryonic ectoderm differentiation, ectoplacental cone cavity closure, and chorioallantoic attachment.

Therapeutic significance:

ERF's involvement in diseases such as Craniosynostosis 4 and Chitayat syndrome, characterized by abnormal skull growth and a complex of facial and digital anomalies respectively, highlights its potential as a therapeutic target. Understanding the role of ETS domain-containing transcription factor ERF could open doors to potential therapeutic strategies for these conditions.